Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 3/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | SCN1A | P35498 | 6/20 | 0.32 |
| ▸ | SCN8A | Q9UQD0 | 6/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19968843 | 0.90 | ABL1 (0.38) | KMOGHSRSMOABL1HTR6 | |
| Hydrochloric Acid SCHEMBL19951387 | 0.89 | ABL1 (0.38) | KMOGHSRSMOABL1HTR6 | |
| SCHEMBL29464868 | 0.83 | GHSR (0.38) | KMOGHSRSMOABL1SCN1A | |
| SCHEMBL19925201 | 0.83 | GHSR (0.38) | KMOGHSRSMOABL1SCN1A | |
| SCHEMBL23748045 | 0.83 | ALDH1A1 (0.38) | KMOSMOABL1 | |
| SCHEMBL19928774 | 0.82 | ABL1 (0.34) | KMOGHSRSMOSLC22A12ABL1 | |
| SCHEMBL19925071 | 0.82 | HTR3E (0.39) | GHSRSLC22A12CCNT1CDK9 | |
| SCHEMBL19927782 | 0.82 | ABL1 (0.32) | KMOGHSRSMOABL1SCN1A | |
| SCHEMBL19951361 | 0.81 | ABL1 (0.34) | SMOABL1 | |
| SCHEMBL29464458 | 0.81 | ABL1 (0.34) | SMOABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | KMO 1893/4885GHSR 2080/4885SMO 258/4885 |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | KMO 1893/4885GHSR 2080/4885SMO 258/4885 |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | KMO 1893/4885GHSR 2080/4885SMO 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.